Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1638
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18357976 | METHODS OF CELL THERAPIES | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 18318305 | TREATING OF NEUROLOGICAL DISORDERS USING EXTRACELLULAR VESICLES RELEASED BY HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED NEURAL STEM CELLS | Non-Final OA | THE TEXAS A&M UNIVERSITY SYSTEM |
| 18332380 | GENERATION OF NEXT GENERATION RECOMBINANT AAV GENE THERAPY VECTORS THAT ADOPT 3D CONFORMATION | Non-Final OA | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 18551038 | PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | Non-Final OA | Pfizer Inc. |
| 18556678 | ENGINEERING PROBIOTIC FOR DEGRADING URIC ACID, AND CONSTRUCTION METHOD THEREFOR AND USE THEREOF | Non-Final OA | SHANDONG UNIVERSITY |
| 18320106 | COMPOSITION AND METHODS FOR 3D CULTURE OF ISLET CELLS | Non-Final OA | CITY OF HOPE |
| 18209726 | RECOMBINANT PLASMID FOR MANUFACTURING BIO-BASED MATERIALS | Non-Final OA | NATIONAL CHUNG HSING UNIVERSITY |
| 18290257 | PRODUCTION OF ENGINEERED T CELLS FROM STEM CELLS | Non-Final OA | Appia Bio, Inc. |
| 18273631 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC FCRN | Non-Final OA | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
| 18311464 | PROTECTION FROM OVARIAN FAILURE BY LOW DOSE INTERLEUKIN-2 ADMINISTRATION | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18262909 | COMPOSITIONS AND METHODS FOR TREATING SPINAL CORD INJURIES | Non-Final OA | ASTERIAS BIOTHERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy